Phylomics detects multiple types of cancer, at the earliest stage, when treatment is most effective
What's the big deal?
A growing number of Americans are becoming patients.
1) Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
2) Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317(23):2402-2416. [PubMed Abstract]
Lifetime Risk (Percent) of Dying from Cancer by Site and Race/Ethnicity: Males, Total US, 2012-2014 (Table 1.19)https://seer.cancer.gov/csr/1975_2014/results_merged/topic_lifetime_risk.pdf and Females, Total US, 2012-2014 (Table 1.20) https://seer.cancer.gov/csr/1975_2014/results_merged/topic_lifetime_risk.pdf. Accessed on January 3, 2018.act]
Why is early detection important?
Survival rates improve dramatically when cancer is detected early, when treatment is most effective.
Looking for non-cell indicators of real-time changes in gene expression, immune activity, and proteins.
Intelligent model decomposes complex genomic, proteomic, and metabolomic datasets to reveal clinically actionable insights.
Our multidimensional tools show the relatedness between subgroups of healthy and diseased individuals and the latter's shared aberrations.